A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating The Efficacy, Safety And Tolerability Of Cariprazine In Patients With Bipolar I Depression

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating The Efficacy, Safety And Tolerability Of Cariprazine In Patients With Bipolar I Depression

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Bipolar I disorders
  • Focus Therapeutic Use
  • Sponsors Allergan; Forest Laboratories
  • Most Recent Events

    • 06 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 24 Jun 2016 Planned End Date changed from 1 Jun 2018 to 1 Jul 2018.
    • 24 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top